Alternative Splicing as a Target for Cancer Treatment.

Alternative Splicing as a Target for Cancer Treatment.
复制标题

DOI:
10.3390/ijms19020545
复制
发表时间:
2018-02-11
影响因子:
5.6
通讯作者:
Martinez-Contreras R
Martinez-Contreras R
中科院分区:
生物学2区
文献类型:
--
作者:
Martinez-Montiel N;Rosas-Murrieta NH;Anaya Ruiz M;Monjaraz-Guzman E;Martinez-Contreras R

文献摘要

参考文献

被引文献

相似文献

选择性剪接是后生动物基因表达的关键机制决定因素。在选择性剪接过程中,由于序列元件和参与剪接调控的细胞因素的结合,非编码序列被移除以产生不同的成熟信使RNA。在选择性剪接过程中,可以选择剪接位点、外显子或内含子序列、互斥外显子或保留内含子的不同组合,以产生不同的成熟mRNAs,进而产生不同的蛋白质产品。选择性剪接是蛋白质多样性的主要来源,负责人类90%的基因表达,最近它已经成为癌症的标志,作为一种完全有潜力的预后和治疗工具。目前,超过15,000个选择性剪接事件与肿瘤生物学的不同方面有关,包括细胞增殖和侵袭、细胞凋亡抵抗和对不同化疗药物的敏感性。在这里,我们介绍了在不同癌症相关基因中发生的公认的和新发现的剪接事件,它们通过几种方法进行修改,以及开发的关键工具的现状,目的是针对具有诊断和治疗目的的选择性剪接。
Alternative splicing is a key mechanism determinant for gene expression in metazoan. During alternative splicing, non-coding sequences are removed to generate different mature messenger RNAs due to a combination of sequence elements and cellular factors that contribute to splicing regulation. A different combination of splicing sites, exonic or intronic sequences, mutually exclusive exons or retained introns could be selected during alternative splicing to generate different mature mRNAs that could in turn produce distinct protein products. Alternative splicing is the main source of protein diversity responsible for 90% of human gene expression, and it has recently become a hallmark for cancer with a full potential as a prognostic and therapeutic tool. Currently, more than 15,000 alternative splicing events have been associated to different aspects of cancer biology, including cell proliferation and invasion, apoptosis resistance and susceptibility to different chemotherapeutic drugs. Here, we present well established and newly discovered splicing events that occur in different cancer-related genes, their modification by several approaches and the current status of key tools developed to target alternative splicing with diagnostic and therapeutic purposes.
DOI: 10.3389/fphar.2015.00070
发表时间: 2015
影响因子: 5.6
作者:
Chon HJ;Bae KJ;Lee Y;Kim J
通讯作者: Kim J
DOI: 10.1073/pnas.0506281103
发表时间: 2006-02-14
影响因子: 11.1
作者:
Burd, CJ;Petre, CE;Knudsen, KE
通讯作者: Knudsen, KE
DOI: 10.1016/j.molonc.2016.08.001
发表时间: 2016-11-01
期刊: MOLECULAR ONCOLOGY
影响因子: 6.6
作者:
de Miguel, Fernando J.;Pajares, Maria J.;Pio, Ruben
通讯作者: Pio, Ruben
DOI: 10.18632/oncotarget.2609
发表时间: 2014-11-30
期刊: Oncotarget
影响因子: --
作者:
Bria E;Di Modugno F;Sperduti I;Iapicca P;Visca P;Alessandrini G;Antoniani B;Pilotto S;Ludovini V;Vannucci J;Bellezza G;Sidoni A;Tortora G;Radisky DC;Crinò L;Cognetti F;Facciolo F;Mottolese M;Milella M;Nisticò P
通讯作者: Nisticò P
DOI: 10.1158/1535-7163.mct-09-0051
发表时间: 2009-08
影响因子: 5.7
作者:
Albert BJ;McPherson PA;O'Brien K;Czaicki NL;Destefino V;Osman S;Li M;Day BW;Grabowski PJ;Moore MJ;Vogt A;Koide K
通讯作者: Koide K